Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis

Diabetes Research and Clinical Practice

Volumn 87, Issue 1, 2010, Pages 98-107

  Baker, William L ^a,b   Talati, Ripple ^a,b   White, C Michael ^a,b   Coleman, Craig I ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

HOMA; Insulin sensitivity; Meta analysis; QUICKI; Statin

Indexed keywords

ATORVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; FAMILIAL HYPERLIPEMIA; HUMAN; HYPERCHOLESTEROLEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; META ANALYSIS; METABOLIC SYNDROME X; RISK REDUCTION; SYSTEMATIC REVIEW;

ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY SIZE; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; INSULIN RESISTANCE; MALE; PATIENT SELECTION; PRAVASTATIN; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; SULFONAMIDES; TRIGLYCERIDES;

EID: 73749087527     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.10.008     Document Type: Article

References (55)

1. Colhoun H.M., Betteridge D.J., and Hitman G.M. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Lancet 364 (2004) 658-696
2. Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations. Lancet 359 (2002) 1379-1387
3. Sever P.S., Dahlor B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). Lancet 361 (2003) 1149-1158
4. Heart Protection Study Collaborative Group. MCR/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals. Lancet 360 (2002) 7-22
5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care. JAMA 288 (2002) 2998-3007
6. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., et al. Pravastatin in Elderly individuals at Risk of Vascular Disease (PROSPER). Lancet 360 (2002) 1623-1630
7. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., et al., for the Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 (2002) 3215-3222
8. Downs J.R., Clearfield M., Tyroler H.A., Whitney E.J., Kruyer W., Langendorfer A., et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 87 (2001) 1074-1079
9. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
10. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
11. Kjekshus J., Apetrei E., Barrios V., Bohm M., Cleland J.G.H., Cornel J.H., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
12. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
13. Dale K.M., White C.M., Henyan N.N., Kluger J., and Coleman C.I. Impact of statin dosing intensity on transaminase and creatine kinase. Am J Med 120 (2007) 706-712
14. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., and White C.M. Statins and cancer risk: a meta-analysis. JAMA 295 (2006) 74-80
15. Alsheikh-Ali A.A., Trinkalinos T.A., Kent D.M., and Karas R.H. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 52 (2008) 1141-1147
16. Freeman D.J., Norrie J., Sattar N., Neely D.G., Cobbe S.M., Ford I., et al. Pravastatin in the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103 (2001) 357-362
17. Coleman C.I., Reinhart K., Kluger J., and White C.M. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin 24 (2008) 1359-1362
18. Ridker P.M., Danielson E., Fonseca F.A.H., Gonest J., Gotto A.M., Kastelein J.J.P., et al., for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 359 (2008) 2195-2207
19. Koh K.K., Quon M.J., Han S.H., Lee Y., Ahn J.Y., Kim S.J., et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 31 (2008) 776-782
20. Koh K.K., Quon M.J., Han S.H., Lee Y., Kim S.J., Park J.B., et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 204 (2009) 483-490
21. Kostapanos M.S., Milionis H.J., Lagos K.G., Rizos C.B., Tselepis A.D., and Elisaf M.S. Baseline triglyceride levels in insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol 590 (2008) 327-332
22. Sviridov D., Hoang A., Ooi E., Watts G., Barrett P.H.R., and Nestel P. Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis 197 (2008) 732-739
23. Ooi E.M.M., Barrett P.H.R., Chan D.C., Nestel P.J., and Watts G.F. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. Atherosclerosis 197 (2008) 139-146
24. Sugiyama S., Fukushima H., Kugiyama K., Maruyoshi H., Kojima S., Funahashi T., et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 194 (2007) e43-e51
25. Deveraj S., Siegel D., and Jialal I. Simvastati (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol 100 (2007) 1397-1399
26. Huptas S., Geiss H.C., Otto C., and Parhofer K.G. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol 98 (2006) 66-69
27. Ganange-Yared M.H., Azar R.R., Amm-Azar M., Khalife S., Germanos-Haddad M., Neemtallah R., et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 54 (2005) 947-951
28. ter Avest E., Abbink E.J., de Graaf J., Tack C.J., and Stalenhoef A.F.H. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidemia. Eur J Clin Invest 35 (2005) 558-564
29. Stalenhoef A.F.H., Ballantyne C.M., Sarti C., Murin J., Tonstad S., Rose H., et al. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. Eur Heart J 26 (2005) 2664-2672
30. Watts F.H., Barrett P.H.R., Ji J., Serone A.P., Chan D.C., Croft K.D., et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52 (2003) 803-811
31. Costa A., Casamitjana R., Casals E., Alvarez L., Morales J., Masramon X., et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med 20 (2003) 743-745
32. Altunbas H., Balci M.K., and Karayalcin U. No effect of simvastatin treatment on insulin sensitivity in patients with primary hypercholesterolemia. Endocr Res 29 (2003) 265-275
33. Jula A., Marniemi J., Huupponen R., Virtanen A., Rastas M., and Ronnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men. A randomized controlled trial. JAMA 287 (2002) 598-605
34. Chan D.C., Watts F.G., Barret P.H.R., Beilin L.J., and Mori T.A. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 48 (2002) 877-883
35. The Cochrane Collaboration. In: Higgins J.P.T., and Green S. (Eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008] (2008). http://www.cochrane-handbook.org/ Available from www.cochrane-handbook.org. Accessed 12/4/2008
36. Wong S.S.L., Wilczynski N.L., and Haynes R.B. Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE. J Med Libr Assoc 94 (2006) 451-455
37. Muniyappa R., Lee S., Chen H., and Quon M.J. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 294 (2008) E15-E26
38. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
39. Wallace T.M., Levy J.C., and Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 27 (2004) 1487-1495
40. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
41. Fujiwara S., Motoyama K., Morioka T., Komatsu M., Tahara H., Koyama H., et al. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment are useful indexes of insulin resistance in type 2 diabetic patients with wide range of fasting plasma glucose. J Clin Endocrinol Metab 89 (2004) 1481-1484
42. Dersimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
43. Follman D., Elliott P., Suh I., and Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45 (1992) 731-769
44. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
45. Veerkamp M.J., de Graaf J., Hendriks J.C.M., Demacker P.N.M., and Stalenhoef A.F.H. Nomogram to diagnose familial combined hyperlipidemia on the bases of results of a 5-year follow-up study. Circulation 109 (2004) 2980-2985
46. Sabatine M.S., Wiviott S.D., Morrow D.A., McCabe C.H., Cannon C.P., and for the TIMI Study Group. High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation 110 Suppl. III (2004) III-834
47. Hanefeld M., Marx N., Pfutzner A., Baurecht W., Luuben G., Karagiannis E., et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity c-reactive protein. The PIOSTAT study. J Am Coll Cardiol 49 (2007) 290-297
48. Tripathy D., Banerji M.A., Bray G.A., Buchanan T.A., Clement S., Henry R.R., et al. ACTos NOW for the prevention of diabetes (ACT NOW) study. Diabetologia 51 Suppl. 1 (2008) S1-S588 (Abstract)
49. Nakata M., Nagasaka S., Kusaka I., Matsuoka H., Ishibashi S., and Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic control. Diabetologia 49 (2006) 1881-1892
50. Mita T., Watada H., Nakayama S., Abe M., Ogihara T., Shimizu T., et al. Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr J 54 (2007) 441-447
51. White C.M. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 42 (2002) 963-970
52. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fund Clin Pharmacol 19 (2004) 117-125
53. 2+ channels in rat islet β-cells. Br J Pharmacol 126 (1999) 1205-1213
54. Masters B.A., Palmoski M.J., Glint O.P., Gregg R.E., Wang-Iverson D., and Durham S.K. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductast inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 131 (1995) 163-174
55. Gotzsche P.C., Hrobjartsson A., Marie K., and Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. JAMA 298 (2007) 430-437